About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
JCO Precision Oncology
›
top-articles
JCO Precision Oncology
3.4
(top 10%)
impact factor
1.1K
(top 20%)
papers
14.5K
(top 20%)
citations
44
(top 20%)
h
-index
3.5
(top 10%)
impact factor
1.3K
all documents
16.8K
doc citations
89
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology
2017
1,266
2
Landscape of Microsatellite Instability Across 39 Cancer Types
JCO Precision Oncology
2017
796
3
Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia
JCO Precision Oncology
2019
429
4
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy
JCO Precision Oncology
2018
343
5
Acral Lentiginous Melanoma Harboring a
ROS1
Gene Fusion With Clinical Response to Entrectinib
JCO Precision Oncology
2017
309
6
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
JCO Precision Oncology
2017
286
7
PTEN
Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
JCO Precision Oncology
2017
275
8
Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
JCO Precision Oncology
2018
215
9
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data
JCO Precision Oncology
2017
209
10
Analysis of
NTRK
Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
JCO Precision Oncology
2018
201
11
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in
ROS1
-Positive Non–Small-Cell Lung Cancer
JCO Precision Oncology
2017
158
12
CDK12
-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
JCO Precision Oncology
2020
138
13
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious
BRCA
Mutation
JCO Precision Oncology
2018
129
14
Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an
NTRK
Gene Fusion
JCO Precision Oncology
2018
112
15
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
JCO Precision Oncology
2017
107
16
Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an
HLA-DRB1-MET
Gene Fusion
JCO Precision Oncology
2017
103
17
Pan-Cancer Analysis of
BRCA1
and
BRCA2
Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
JCO Precision Oncology
2020
103
18
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
JCO Precision Oncology
2018
101
19
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology
2018
98
20
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
JCO Precision Oncology
2017
96
21
Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors
JCO Precision Oncology
2018
95
22
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
JCO Precision Oncology
2020
93
23
Cholangiocarcinoma With
FGFR
Genetic Aberrations: A Unique Clinical Phenotype
JCO Precision Oncology
2018
86
24
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA
JCO Precision Oncology
2018
86
25
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance
JCO Precision Oncology
2019
83
26
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model
JCO Precision Oncology
2019
81
27
Immunophenotype and Response to Immunotherapy of
RET
-Rearranged Lung Cancers
JCO Precision Oncology
2019
73
28
Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
JCO Precision Oncology
2020
69
29
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
JCO Precision Oncology
2020
67
30
Detection of Early Human Papillomavirus–Associated Cancers by Liquid Biopsy
JCO Precision Oncology
2019
64
31
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States
JCO Precision Oncology
2018
63
32
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
JCO Precision Oncology
2019
63
33
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
JCO Precision Oncology
2020
62
34
Majority of
B2M
-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High
JCO Precision Oncology
2019
61
35
Acquired
ALK
and
RET
Gene Fusions as Mechanisms of Resistance to Osimertinib in
EGFR
-Mutant Lung Cancers
JCO Precision Oncology
2018
60
36
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
JCO Precision Oncology
2019
58
37
Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board
JCO Precision Oncology
2017
57
38
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
JCO Precision Oncology
2017
57
39
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
JCO Precision Oncology
2021
55
40
Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma
JCO Precision Oncology
2018
52
41
Palbociclib in Patients With Non–Small-Cell Lung Cancer With
CDKN2A
Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology
2020
52
42
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
JCO Precision Oncology
2020
52
43
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma
JCO Precision Oncology
2017
51
44
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
JCO Precision Oncology
2019
51
45
CDK12
-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade
JCO Precision Oncology
2020
51
46
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
JCO Precision Oncology
2017
50
47
MET
Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
JCO Precision Oncology
2021
50
48
Influence of
TP53
Mutation on Survival in Patients With Advanced
EGFR
-Mutant Non–Small-Cell Lung Cancer
JCO Precision Oncology
2018
49
49
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations
JCO Precision Oncology
2019
47
50
Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
JCO Precision Oncology
2018
46
site/software ©
exaly
; All materials licenced under
CC by-SA
.